MedTrace Logo

Essential Hypertension

NCT01264692 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 196

Last updated 2018-09-27

No results posted yet for this study

Summary

The purpose of this study is to demonstrate the antihypertensive efficacy of once daily oral administration of ACT 280778 on DBP compared to placebo after 28 days.

Conditions

  • Essential Hypertension

Interventions

DRUG

ACT-280778

10 mg once daily for 28 ± 2 days

DRUG

Placebo

Placebo oral capsules matching ACT-280778

DRUG

Amlodipine

10 mg once daily for 28 ± 2 days

Sponsors & Collaborators

  • Idorsia Pharmaceuticals Ltd.

    lead INDUSTRY

Principal Investigators

  • Kasra Shakeri-Nejad, MD, PhD · Actelion

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-01-31
Completion
2012-02-29

Countries

  • Israel
  • Serbia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01264692 on ClinicalTrials.gov